Reference

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., Zhou, X., Luo, H., Mao, Z., Chen, X., Xie, J., Liu, J., Cheng, H., Zhao, J., Huang, G., Wang, W., … Zhou, J. (2020). Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. The Journal of allergy and clinical immunology, 146(1), 137–146.e3. https://doi-org.proxy1.library.jhu.edu/10.1016/j.jaci.2020.05.019

0

1

Updated 2020-07-25

Contributors are:

Who are from:

Tags

SARS-CoV-2 (COVID-19)

Biomedical Sciences